Stock Events

Stock Events

Aurinia Pharmaceuticals 

$16.03
134
-$0.19-1.17% Today

Statistics

Day High
16.48
Day Low
16.02
52W High
16.88
52W Low
7.29
Volume
73,049,901
Avg. Volume
-
Mkt Cap
2.13B
P/E Ratio
7.32
Dividend Yield
-
Dividend
-

Upcoming

Earnings

30JulExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-0.02
0.07
0.16
0.25
Expected EPS
0.242
Actual EPS
N/A

Financials

101.47%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
566.11MRevenue
574.4MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow AUPH. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
GSK
GSK
Mkt Cap106.31B
GlaxoSmithKline develops treatments in areas similar to Aurinia, including autoimmune diseases, making them a direct competitor.
Abbvie
ABBV
Mkt Cap402.35B
AbbVie competes in the immunology space, offering drugs that could be alternatives to Aurinia's products.
Pfizer
PFE
Mkt Cap149.38B
Pfizer has a broad portfolio that includes treatments for autoimmune diseases, directly competing with Aurinia's offerings.
Bristol-Myers Squibb
BMY
Mkt Cap116.66B
Bristol Myers Squibb has a strong presence in the immunology and oncology sectors, areas where Aurinia is also aiming to make an impact.
AMGEN
AMGN
Mkt Cap191.7B
Amgen focuses on novel therapeutics in areas including inflammation, which overlaps with Aurinia's focus on autoimmune diseases.
Johnson & Johnson
JNJ
Mkt Cap579.83B
Johnson & Johnson, through its pharmaceutical division Janssen, competes in the autoimmune disease market.
Novartis
NVS
Mkt Cap292.07B
Novartis offers a range of treatments for autoimmune diseases, competing with Aurinia's lupus nephritis treatment.
Gilead Sciences
GILD
Mkt Cap155.93B
Gilead Sciences has a focus on inflammatory and respiratory diseases, making it a competitor in the autoimmune treatment market.
Astrazeneca
AZN
Mkt Cap277.22B
AstraZeneca has a diverse portfolio that includes treatments for lupus, directly competing with Aurinia's lupus nephritis drug.
Roche
RHHBY
Mkt Cap332.67B
Roche, through its Genentech division, develops medications for autoimmune diseases, including lupus, making it a competitor.

About

Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United States and internationally. The company's flagship product is LUPKYNIS, an approved treatment designed for adult individuals suffering from active lupus nephritis. Furthermore, Aurinia maintains a strategic collaboration and licensing agreement with Otsuka Pharmaceutical Co., Ltd. The firm's main corporate office is located in Victoria, Canada.
Show more...
CEO
Mr. Kevin C. Tang
Employees
130
Country
United States
ISIN
CA05156V1022

Listings

STU
DE
IKAP.STU
MU
DE
IKAP.MU
LSE
GB
0UJF.LSE
F
DE
IKAP.F

0 Comments

Share your thoughts

FAQ

What is Aurinia Pharmaceuticals stock price today?▼
The current price of AUPH is $16.03 USD — it has decreased by -1.17% in the past 24 hours. Watch Aurinia Pharmaceuticals stock price performance more closely on the chart.
What is Aurinia Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Aurinia Pharmaceuticals stocks are traded under the ticker AUPH.
Is Aurinia Pharmaceuticals stock price growing?▼
AUPH stock has risen by +3.19% compared to the previous week, the month change is a +5.76% rise, over the last year Aurinia Pharmaceuticals has showed a +104.3% increase.
What is Aurinia Pharmaceuticals market cap?▼
Today Aurinia Pharmaceuticals has the market capitalization of 2.13B
When is the next Aurinia Pharmaceuticals earnings date?▼
Aurinia Pharmaceuticals is going to release the next earnings report on July 30, 2026.
What were Aurinia Pharmaceuticals earnings last quarter?▼
AUPH earnings for the last quarter are 0.25 USD per share, whereas the estimation was 0.2 USD resulting in a +28.21% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Aurinia Pharmaceuticals revenue for the last year?▼
Aurinia Pharmaceuticals revenue for the last year amounts to 566.11M USD.
What is Aurinia Pharmaceuticals net income for the last year?▼
AUPH net income for the last year is 574.4M USD.
How many employees does Aurinia Pharmaceuticals have?▼
As of June 17, 2026, the company has 130 employees.
In which sector is Aurinia Pharmaceuticals located?▼
Aurinia Pharmaceuticals operates in the Health & Wellness sector.
When did Aurinia Pharmaceuticals complete a stock split?▼
Aurinia Pharmaceuticals has not had any recent stock splits.
Where is Aurinia Pharmaceuticals headquartered?▼
Aurinia Pharmaceuticals is headquartered in Edmonton, United States.